Harvard Malaria Forum – Rethinking R&D in the New Era of Malaria Eradication

Rethinking Malaria R&D

Harvard University is dedicated to maintaining and advancing the remarkable results achieved so far in the fight against malaria. This year’s Harvard Malaria Forum–“Rethinking R&D in the New Era of Malaria Eradication”–brought together leaders at the intersection of public-private partnerships, in particular those from pharmaceutical, biotech and agro-chemical industries, and academia, to discuss and explore actionable solutions and new R&D approaches to eradicate malaria.

The Harvard Malaria Forum featured leaders in global malaria discussing the knowledge gaps and major biological and clinical roadblocks in our understanding of Plasmodium falciparum and Plasmodium vivax. The Forum was sponsored by the Harvard Business School, the Harvard Medical School, the Harvard School of Public Health, Harvard University’s Office of Technology Development, and the Harvard Global Health Institute. The Forum was also a special event of the Harvard School of Public Health’s Centennial Celebration.

Tuesday, October 22, 2013, 9:00am-12:00pm
(Networking & Breakfast – 8:30am / Networking & Lunch – 12pm)
Harvard Hall, Harvard Club of Boston

Julio Frenk, MPH, MD, PhD, Dean of the Faculty, HSPH

Opening Remarks
David Golan, MD, PhD, Dean for Graduate Education, Harvard Medical School

Dyann Wirth, PhD, Richard Pearson Strong Professor and Chair, Department of Immunology and Infectious Diseases, HSPH

Pedro Alonso, PhD, Director, Barcelona Institute for Global Health
Ashley Birkett, PhD, Director, PATH Malaria Vaccine Initiative (MVI)
Flaminia Catteruccia, PhD, Associate Professor of Immunology and Infectious Diseases, HSPH
Thierry Diagana, PhD, Head, Drug Discovery Unit, Novartis Institute for Tropical Diseases
Manoj Duraisingh, PhD, Associate Professor of Immunology and Infectious Diseases, HSPH
Nick Hamon, PhD, CEO, Innovative Vector Control Consortium (IVCC)
Joseph Lassiter, PhD, Professor of Management Practice in Environmental Management, HBS
David Reddy, PhD, CEO, Medicines for Malaria Venture (MMV)


Rethinking malaria R&D sponsors